Abivax S.A. (ABVX) Stock: Price, Forecast & Analyst Target
Abivax S.A. (ABVX) — MoonshotScore 52/100 (Fair band), calculated Oct 6, 2026. Price $91.73 (-1.24%), as of the Oct 5, 2026 trading session; market cap $6.73B. Expected results Dec 21, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Abivax S.A. · ABVX · NASDAQ · Healthcare · Biotechnology
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Abivax (ABVX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but stalling growth. Business Quality: Solid; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $0 (Q4 FY2025, quarter ended Dec 2025)
- EPS beat 3 of 8
- Altman Z 33.06 · Piotroski F 3
Holding back: soft growth
Helping: business quality, balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 53 | Fair | |
| 53 | Fair | |
| 53 | Fair | |
| 52 | Fair | |
| 52 | Fair | |
| 52 | Fair |
The score was 52 in the stored Oct 5, 2026 snapshot and remains 52 in the current publication computed Oct 6, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $91.73 |
| Change on the day | -1.24% |
| 52-week range | $69.81–$148.83 |
| Market capitalisation | $6.73B |
| Shares traded on the day | 840.2K |
| Beta (volatility vs the S&P 500) | -0.25 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Abivax (ABVX): Split View
53/100 · BCouncil is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 6, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the ABVX film — every key number, told as a short cinematic story
~2 min · open the film
What is Abivax (ABVX), and what does it report?
Short answer · as of
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. Abivax S.A. (ABVX) is listed on NASDAQ. Abivax S.A. (ABVX) is classified as Healthcare / Biotechnology. SEC filing business address: 7 BD Haussmann, Paris. It employs 80 people and is led by Marc de Garidel. In Q4 FY2025 it reported revenue of $0 and net income of -$323M. The market values it at $6.73B.
What do the latest results show for Abivax (ABVX)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $0. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.37M Sep 21, 2026
- Latest report · revenue estimate
- $799,166 Sep 21, 2026
- Latest report · revenue vs estimate
- Above estimate Sep 21, 2026
- Latest report · EPS vs estimate
- Below estimate Sep 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 21, 2026 | $1.37M | $799,166 | −$1.7100 | −$1.0287 |
| May 22, 2026 | $1.51M | $401,125 | −$0.7100 | −$1.0700 |
| Mar 23, 2026 | $515,064 | $1.80M | −$1.1900 | −$1.7000 |
| Dec 15, 2025 | $2.40M | $1.35M | −$2.4717 | −$0.7865 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $0 | -$323M | -$4.65 (diluted) |
| Q2 FY2025 | $0 | -$54M | -$0.86 (diluted) |
| Q4 FY2024 | $0 | -$59M | -$0.93 (diluted) |
| Jun 2024 | $0 | -$44M | -$0.69 (diluted) |
What are the financial strengths and risks for Abivax (ABVX)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 33.06 · Piotroski F 3. Trailing ratios: ROA -57.5% · current ratio 8.75 · earnings yield -4.3% · free-cash-flow yield -1.8%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Abivax (ABVX)?
Short answer · as of
The next earnings report is expected on Dec 21, 2026. The number it tests is the $-3.70 EPS analysts carry for it. Analyst estimates on file carry FY2026 revenue $4.01M · EPS -3.70 · 9 analysts. Current published price targets run low $118.00 · high $180.00 · consensus $156.00 · median $156.50 against a quoted price of $91.73 (as of Oct 5, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2025) was filed Mar 23, 2026 — 6 months ago.
Checked against the records this page reads, on the dates shown above.
How does Abivax compare with its peers?
Short answer
Abivax's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $334.85 Oct 5, 2026 | $9.50B | 98 5-pillar Oct 6, 2026 | |
| $306.77 Oct 5, 2026 | $6.15B | 96 5-pillar Oct 6, 2026 | |
| $122.03 Oct 5, 2026 | $13.1B | 91 5-pillar Oct 6, 2026 | |
| $30.39 Oct 5, 2026 | $8.54B | 90 5-pillar Oct 6, 2026 | |
| $140.63 Oct 5, 2026 | $9.08B | 76 5-pillar Oct 6, 2026 | |
| $159.18 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 6, 2026 | |
| $84.38 Oct 5, 2026 | $5.09B | 68 5-pillar Oct 6, 2026 | |
| $53.91 Oct 5, 2026 | $8.18B | 65 5-pillar Oct 6, 2026 | |
| $42.76 Oct 5, 2026 | $7.17B | 64 5-pillar Oct 6, 2026 | |
| $118.87 Oct 5, 2026 | $4.97B | 64 5-pillar Oct 6, 2026 | |
| $14.72 Oct 5, 2026 | $5.06B | 62 5-pillar Oct 6, 2026 | |
| Abivax (ABVX) — this page | $91.73 | $6.73B | 52 |
| $236.04 Oct 5, 2026 | $14.8B | 40 5-pillar Oct 6, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $118.00 – $180.00
- Consensus target
- $156.00
- Median target
- $156.50
- Revenue estimate
- $4.01M
- EPS estimate
- $-3.70
Consensus record · Captured .
Measured against a quoted price of $91.73 (as of Oct 5, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 79.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 72.0% Prior to period end Jun 30, 2026
- Reporting holders
- 367 Period end Jun 30, 2026
- Previous quarter · holders
- 286 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Tcg Crossover Management, LLC | 6,007,834 |
| Darwin Global Management, Ltd. | 3,621,583 |
| Helikon Investments Ltd | 2,787,131 |
| Susquehanna International Group, Llp | 2,458,800 |
| Vestal Point Capital, LP | 2,349,443 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Abivax (ABVX)?
Abivax Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ABVX research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ABVX?
ABVX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ABVX a good stock to buy?
Stock Expert AI does not rate ABVX buy, sell or hold. Abivax S.A. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ABVX stock price today?
The last price recorded on this page for Abivax S.A. (ABVX) is $91.73, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ABVX price target?
The analyst consensus price target for Abivax S.A. (ABVX) is $156.00 (range $118.00 to $180.00, median $156.50), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for ABVX?
The primary risks for Abivax S.A. stem from the inherent uncertainties of drug development. These include the potential for clinical trial failures at any stage, which could significantly impede product development and market prospects.
What are the key factors to evaluate for ABVX?
Abivax S.A. (ABVX) holds a MoonshotScore in the moderate range. Analysts target $156.00 (+70%). Engages in early-stage research programs for infectious diseases such as Dengue fever, influenza, and respiratory syncytial virus. Not financial advice.
How frequently does ABVX data refresh on this page?
ABVX's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ABVX's recent stock price performance?
Abivax S.A. (ABVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABVX overvalued or undervalued right now?
Abivax S.A. (ABVX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $156.00 (+70%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (56 figures)
The 56 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 7 BD Haussmann, Paris | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "7-11 Boulevard Haussmann, Paris, IF, 75009, FR". |
FMP — 44 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $91.73 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T21:44:40.440Z. | |
px.change | Change on the day | -1.24% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $6.73B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-05. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Dec 21, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$1.15 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $69.81–$148.83 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 840.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | -0.25 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 80 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Marc de Garidel | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q4 FY2025 | -$323M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-09-21.revenue_actual | Revenue · reported — report date 2026-09-21 | $1.37M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-21.revenue_estimated | Revenue · estimate — report date 2026-09-21 | $799,166 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-21.eps_actual | EPS · reported — report date 2026-09-21 | −$1.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-09-21.eps_estimated | EPS · estimate — report date 2026-09-21 | −$1.0287 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-22.revenue_actual | Revenue · reported — report date 2026-05-22 | $1.51M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-22.revenue_estimated | Revenue · estimate — report date 2026-05-22 | $401,125 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-22.eps_actual | EPS · reported — report date 2026-05-22 | −$0.7100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-22.eps_estimated | EPS · estimate — report date 2026-05-22 | −$1.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-23.revenue_actual | Revenue · reported — report date 2026-03-23 | $515,064 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-23.revenue_estimated | Revenue · estimate — report date 2026-03-23 | $1.80M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-23.eps_actual | EPS · reported — report date 2026-03-23 | −$1.1900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-23.eps_estimated | EPS · estimate — report date 2026-03-23 | −$1.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-15.revenue_actual | Revenue · reported — report date 2025-12-15 | $2.40M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-15.revenue_estimated | Revenue · estimate — report date 2025-12-15 | $1.35M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-15.eps_actual | EPS · reported — report date 2025-12-15 | −$2.4717 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-12-15.eps_estimated | EPS · estimate — report date 2025-12-15 | −$0.7865 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $118.00 · high $180.00 · consensus $156.00 · median $156.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $118.00 – $180.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $156.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $156.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 79.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 72.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 367 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 286 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Tcg Crossover Management, LLC — shares in provider snapshot | 6,007,834 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Darwin Global Management, Ltd. — shares in provider snapshot | 3,621,583 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Helikon Investments Ltd — shares in provider snapshot | 2,787,131 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Susquehanna International Group, Llp — shares in provider snapshot | 2,458,800 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Vestal Point Capital, LP — shares in provider snapshot | 2,349,443 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-28 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 33.06 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -57.5% · current ratio 8.75 · earnings yield -4.3% · free-cash-flow yield -1.8% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2026 | $-3.70 | UNRECORDED | Stored analyst estimates — Captured 2026-10-01 · Expired observation | |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $4.01M · EPS -3.70 · 9 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-10-01 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $4.01M | UNRECORDED | Stored analyst estimates — Captured 2026-10-01 · Expired observation |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-09-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.37M) with the recorded estimate ($799,166) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-09-21.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$1.7100) with the recorded estimate (−$1.0287) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 52 of 100 · Fair · pillars 70 / 84 / 39 / 17 / 39 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 52 (stored snapshot Oct 5, 2026) → 52 (current publication computed Oct 6, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-09-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-09-21.revenue_actual,earn.history.depth.2026-09-21.revenue_estimated,earn.history.depth.2026-09-21.revenue_actual.comparison,earn.history.depth.2026-09-21.eps_actual.comparison,earn.history.depth.2026-09-21.eps_actual,earn.history.depth.2026-09-21.eps_estimated,earn.history.depth.2026-05-22.revenue_actual,earn.history.depth.2026-05-22.revenue_estimated,earn.history.depth.2026-05-22.eps_actual,earn.history.depth.2026-05-22.eps_estimated,earn.history.depth.2026-03-23.revenue_actual,earn.history.depth.2026-03-23.revenue_estimated,earn.history.depth.2026-03-23.eps_actual,earn.history.depth.2026-03-23.eps_estimated,earn.history.depth.2025-12-15.revenue_actual,earn.history.depth.2025-12-15.revenue_estimated,earn.history.depth.2025-12-15.eps_actual,earn.history.depth.2025-12-15.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.